Parkinson's disease (PD) and dementia with Lewy bodies (DLB) share clinical and pathological similarities. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Alzheimer's disease (AD) is the most common form of dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The purpose of this review was to update available knowledge on the relationship between adherence to the Mediterranean diet (MeDi) and cognitive decline, risk of dementia or Alzheimer's Disease (AD), and to analyse the reasons for some inconsistent results across studies. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
As the population ages, risks for cognitive decline threaten independence and quality of life for older adults and present challenges to the health care system. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
There have been increasing efforts to develop cognitive interventions to ameliorate cognitive problems experienced by older adults. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Adherence to a Mediterranean diet has recently been shown to protect against cognitive decline and dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Regular physical activity undoubtedly has many health benefits for all age groups. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
There is a pressing demand for improving the quality and efficacy of health care and social support services needed by the world's growing elderly population, especially by those affected by mild cognitive impairment (MCI) and Alzheimer's disease (AD)-type early-stage dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The rise in the ageing population has resulted in increased incident rates of cognitive impairment and dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Amyloid diseases are characterized by the deposition of typically aggregated proteins/peptides in tissues, associated with degeneration and progressive functional impairment. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
There is a critical need to potentially individualize new strategies able to prevent and to slow down the progression of predementia and dementia syndromes. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The use of positive modulators of PLA2 (especially of cPLA2 and iPLA2) or supplementation with dietary lipid compounds (e.g., arachidonic acid) in combination with cognitive training could be a valuable therapeutic strategy for cognitive enhancement in early-stage AD. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
There was clear evidence of generalization especially in patients with milder semantic impairments. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Non-pharmacological interventions have the potential to reduce cognitive decline and to improve psychosocial aspects in mild cognitive impairment and Alzheimer's dementia, and the absence of side effects makes them a favorable option also for preventive strategies. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Epidemiological work has, however, identified modifiable lifestyle factors, such as poor diet and physical and cognitive inactivity, that are associated with the risk of dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Identifying feasible and effective interventions aimed at mitigating the effects of cognitive decline in older adults is currently a high priority for researchers, clinicians, and policy makers. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Today, tens of millions of elderly individuals worldwide suffer from dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Patients with Alzheimer's disease (AD) gradually lose their cognitive competence, particularly memory, and the ability to perform daily life tasks. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The purpose of this article is to critically review and synthesize the literature on the effects of nonpharmacological cognitive training on dementia symptoms in early-stage Alzheimer's disease (AD) and related dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
It is possible to identify risks or protective factors against dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease, the most common cause of dementia, has a high global economic impact. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
As the number of patients with Alzheimer's disease (AD) is expected to grow, finding ways to prevent and lower the risk of AD becomes a crucial matter. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
36/100
Undernutrition is associated with cognitive decline. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
36/100
Severe nutritional deficiencies, such as protein energy malnutrition and deficiency of nicotinamide, vitamin B(12), folate, and thiamine, have long been recognized to cause severe confusion. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
36/100
A decline of cognitive abilities is a part of normal human ageing. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →